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Abstract
Sanfilippo syndrome type B (MPS IIIB) is characterized by profound mental retardation in childhood, dementia and death in
late adolescence; it is caused by deficiency of a-N-acetylglucosaminidase and resulting lysosomal storage of heparan sulfate.
A mouse model, generated by homologous recombination of the Naglu gene, was used to study pathological changes in
the brain. We found earlier that neurons in the medial entorhinal cortex (MEC) and the dentate gyrus showed a number of
secondary defects, including the presence of hyperphosphorylated tau (Ptau) detected with antibodies raised against Ptau
in Alzheimer disease brain. By further use of immunohistochemistry, we now show staining in neurons of the same area for
beta amyloid, extending the resemblance to Alzheimer disease. Ptau inclusions in the dentate gyrus of MPS IIIB mice were
reduced in number when the mice were administered LiCl, a specific inhibitor of Gsk3b. Additional proteins found elevated
in MEC include proteins involved in autophagy and the heparan sulfate proteoglycans, glypicans 1 and 5, the latter closely
related to the primary defect. The level of secondary accumulations was associated with elevation of glypican, as seen by
comparing brains of mice at different ages or with different mucopolysaccharide storage diseases. The MEC of an MPS IIIA
mouse had the same intense immunostaining for glypican 1 and other markers as MPS IIIB, while MEC of MPS I and MPS II
mice had weak staining, and MEC of an MPS VI mouse had no staining at all for the same proteins. A considerable amount of
glypican was found in MEC of MPS IIIB mice outside of lysosomes. We propose that it is the extralysosomal glypican that
would be harmful to neurons, because its heparan sulfate branches could potentiate the formation of Ptau and beta
amyloid aggregates, which would be toxic as well as difficult to degrade.
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Introduction
The Sanfilippo syndrome comprises four mucopolysaccharide
storage diseases (MPS III A-D) that have similar clinical
phenotypes but are caused by different enzyme deficiencies in
the lysosomal pathway of heparan sulfate degradation [1]. All four
are characterized by profound mental retardation, behavioral
problems, dementia, and death usually in the second decade,
along with somatic manifestations that are milder than those seen
in other MPS. Each of the MPS III subtypes is genetically
heterogeneous, with some attenuated forms showing slower
progression. We have concentrated on MPS IIIB, which is caused
by mutation in the NAGLU gene and resulting deficiency of a-N-
acetylglucosaminidase, and have made a Naglu knockout mouse by
homologous recombination [2]. Biochemical and pathological
findings plus a much shortened life span indicated that this mouse
could serve as a model for the human disease in order to study
pathogenesis and develop therapy.
Numerous studies of this mouse by our group and by others
have addressed themselves to the neurologic problems of MPS
IIIB. There is a strong inflammatory component in the brain
disease, which is seen as activation of microglia [3,4] with
increased production of cytokines and chemokines [4,5], up-
regulation of immune-related genes [6], and even auto-immunity
[7]. Astrocytes are also activated [8]. Alterations in vision and
hearing as well as in circadian rhythm have been reported [9,10],
comparable to findings in the human disease. Both hypoactivity
[2] and hyperactivity [11] have been noted in the open field test,
but under different experimental conditions. The MPS IIIB mouse
has been used for numerous therapeutic trials, including drugs
[12], enzyme replacement [13] and gene therapy with various
vectors [11,14,15,16,17,18,19].
We had observed that a number of pathological defects
involving neurons were limited to a small areas of the brain of
the MPS IIIB mice, mostly to layer 2 of the medial entorhinal
cortex (MEC). The first defect to be observed in MEC was an
increase in a lysosomal form of SCMAS (subunit c of
mitochondrial ATP synthase) [20], suggesting autophagy or
mitophagy and/or a general reduction in lysosomal proteolysis
(SCMAS is a lipoprotein that is especially difficult to degrade and
accumulates in a number of neurologic storage diseases [21]).
Subsequently, we observed elevated cholesterol, GM3 ganglioside,
ubiquitin and colloidal iron staining for glycosaminoglycans in the
same cells [3,20], as well as an increase in lysozyme and in
hyperphosphorylated tau (Ptau) [22]. Ptau was also found in the
dentate gyrus, which together with the medial entorhinal cortex is
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involved in learning and memory. The presence of Ptau is
reminiscent of Alzheimer disease and other tauopathies, all of
which lead to dementia [23].
The present study extends these findings to other proteins that are
elevated in neurons of the MEC or dentate gyrus in the MPS IIIB
mouse. These were detected by immuno-histochemistry at a sen-
sitivity such that no staining was detected in a comparable area of
unaffected control mice (Naglu +/2) or in an unaffected region of the
MPS IIIB brain (represented by the lateral entorhinal cortex, LEC).
The study seeks to understand the relationship of these secondary
defects to the primary defect, failure to degrade heparan sulfate, as
well as the relationship of the secondary defects to each other.
Results
MEC of MPS IIIB mouse is enriched in glypicans, heparan
sulfate proteoglycans
Since disruption of the lysosomal pathway of heparan sulfate
degradation is the primary cause of MPS IIIB, accumulation of
heparan sulfate should be detectable by immuno-histochemistry.
We were not successful in detecting heparan sulfate glycan with
antibody HepSS-1. However, MEC neurons in the MPS IIIB
brain showed strong staining with antibodies against glypican 1
and glypican 5, two heparan sulfate proteoglycans known to play
an important role in the developing brain [24] (Fig. 1). Glypican
staining was not observed in neurons from the LEC of the mutant
mice nor from the MEC of control mice. There was no staining for
glypican 2 (cerebroglycan), which is also important in early brain
development (not shown); perhaps this proteoglycan is not
expressed in the MEC at the ages tested (1, 3 and 6 months).
The epitopes of the glypican antibodies are in the protein
moiety of the proteoglycan. The carbohydrate moiety was
detected by pre-treating the sections with bacterial heparitinase
(heparan sulfate lyase) and staining the resulting protein-linked
carbohydrate stubs with the monoclonal antibody 3G10 [25].
Staining with 3G10 was most intense in neurons of MEC (Fig. 1)
and to a lesser degree in neurons of the somatosensory cortex (not
shown), but not of LEC. No staining was observed in neurons of
control mice (Naglu +/2). The protein and carbohydrate stains
were generally co-localized in neurons of MEC (Fig. 2, top row),
but the presence of some 3G10 (green) staining not associated with
glypicans 1 and 5 (red) suggests the existence of additional heparan
sulfate proteoglycan(s), although it may also indicate carbohydrate
stubs attached to glypican fragments that had lost their epitope
due to partial proteolysis. No special biological significance is
attributed to the presence of some glypican staining (red) without
3G10 staining (green), as it may be due to incomplete degradation
of the carbohydrate chains by the heparitinase, so that the neo-
epitope is not exposed.
Little glypican staining was seen in lysosomes, as shown by
double staining with antibodies to Lamp 1 This was true whether
the glypican was detected by the protein moiety (Fig. 2, rows 2 and
3) or the carbohydrate moiety (Fig. 2, bottom row). On the other
hand, there was glypican clearly outside of lysosomes, as shown by
the red stain.
MEC of MPS IIIB mouse is enriched in Gsk3b
The previous finding of Ptau in the medial entorhinal cortex
and dentate gyrus of MPS IIIB mice [22] led to testing for Gsk3b,
a candidate kinase. Both Gsk3b and P-Gsk3b (Y216), the form
Figure 1. Elevated level of heparan sulfate proteoglycan in the MEC region of the MPS IIIB brain. Sections were stained, as indicated,
with antibodies against epitopes in the protein core of glypican 1 and glypican 5 and against the carbohydrate neo-epitope 3G10 formed by pre-
treatment of the proteoglycan with heparitinase. The top row shows prominent staining in the MEC region of 6 months old Naglu 2/2 mice, the
middle row shows absence of such staining in the LEC region of these mice, and the bottom row, absence of staining in the MEC region of age-
matched Naglu +/2 (control) mice. The larger image was taken at 10X magnification, and the insert at 40X. The scale bar, 200 mm, applies to all
figures in the panel.
doi:10.1371/journal.pone.0027461.g001
Medial Entorhinal Cortex in Sanfilippo B Mouse
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activated by phosphorylation on tyrosine 216 [26], showed intense
staining in the MEC of the mutant mice, but not in the control
area or in the control mice (Fig. 3).
To determine whether Gsk3b was responsible for the formation
of Ptau, lithium chloride, a selective inhibitor of Gsk3b [27] was
administered to the mice in chow after weaning and the level of Ptau
AT270 inclusions in the dentate gyrus was determined at the age of
90 days. To insure that the pups would be accustomed to the taste of
lithium chloride, the nursing mothers were fed lithium chow from
day P12. Fig. 4 shows that administration of lithium chloride in
chow at a dose of 3g/kg reduced the number of AT270 positive
Ptau inclusions in the dentate gyrus by 60% (p,0.01). A lesser
amount (2 g/kg) had no effect (not shown), whereas a higher
amount (4 g/kg) caused death of several pups and was discontinued.
In contrast to the marked improvement in the dentate gyrus, we did
not observe a change in MEC of immunostaining of Ptau AT100,
beta amyloid, lysozyme, SCMAS, P-Gsk3b(Y216); however, immu-
nostaining is not a quantitative test and might not have revealed a
partial reduction.
MEC of MPS IIIB mouse is enriched in beta amyloid
We found staining for beta amyloid in neurons of MEC of MPS
IIIB mice by using antibodies raised against the 14 N-terminal
amino acids, against the N-terminus of the amyloid precursor
protein (APP), and against Abeta peptides 1–40 and 1–42; such
staining was not found in the control region or unaffected mouse
brain (Fig. 5).
Because beta amyloid is known to form oligomers, we tested
reactivity with A11, an antibody that recognizes the oligomeric
conformation of proteins independent of their sequence [28]. A11
Figure 2. Co-localization of protein and carbohydrate moieties of heparan sulfate proteoglycans and only limited co-localization
with lysosomes. The top row shows considerable but not complete co-localization of staining for the protein core of heparan sulfate proteoglycan
(using a mixture of antibodies against glypican 1 and glypican 5) with staining for the carbohydrate neo-epitope 3G10. Subsequent rows show only
limited co-localization of staining of antibody against Lamp1, a marker for lysosomes, and antibodies against glypican 1, glypican 5 and 3G10. But a
considerable amount of the heparan sulfate proteoglycan, observed by antibodies against glypican 1 or 5 or the carbohydrate neo-epitope 3G10, is
observed outside the area occupied by lysosomes. The mice in this experiment were 3 months old, except for the glypican 5 experiment which used
6 months old mice. The scale bar is 20 mm.
doi:10.1371/journal.pone.0027461.g002
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staining was found in MEC but not in the control region or control
mice (Fig. 5). However, the A11 immunoreactivity could be shared
with oligomers of lysozyme, which is also elevated in MEC
neurons [22].
MEC of MPS IIIB mice is enriched in additional proteins
We have observed immunostaining of the MEC region of MPS
IIIB mice for several other proteins (Fig. 6). These include proteins
involved in autophagy: LC3, P62, and polyubiquitinated protein(s)
[29]; nitrotyrosine-modified protein(s), a marker for oxidative
stress, which has been reported in MPS IIIB brain [5]; and O-
GlcNAc-modified protein(s), a marker for metabolic stress [30].
GM3 ganglioside and total ubiquitin are also shown in Fig. 6,
because the earlier demonstration of their presence in MEC was
indirect (i.e. localization in same cells as SCMAS [20]). The usual
controls (2/2 LEC and +/2 MEC) showed no staining (not
shown).
MEC and dentate gyrus of MPS IIIA mice, but not of other
mouse models of MPS, have the same defects as in MPS
IIIB mice
Immunohistochemical staining showed an elevated level of
glypican 1 and of a number of proteins in the MEC of mice with
MPS IIIA, which have a deficiency of sulfamidase, another
enzyme of heparan sulfate degradation (Fig. 7). These other
proteins were SCMAS, lysozyme, beta amyloid (amino acids 1–
14), nitrotyrosine-modified protein, Ptau AT100, P-Gsk3b (Y216),
LC3, and total ubiquitin. No immunostaining of these markers
was observed in the control region or in MEC of age-matched
C57BL6 mice (not shown). In addition, Ptau AT270 inclusions
were seen in the dentate gyrus, within or at the border of the
granular cell layer of the MPS IIIA mice but not of the C57BL6
mice (Fig. 7, bottom row). Thus the results in the MEC and
dentate gyrus areas of the MPS IIIA brain were similar to those in
the MPS IIIB brain for all markers tested.
The defects found in the MEC of mouse models of other MPS
are shown in Table 1.
There was only weak staining for glypican 1 in the MEC of mice
with MPS I (deficiency of a-L-iduronidase) and MPS II (deficiency
of iduronate sulfatase); staining for the secondary defects was
likewise weak or marginal. There was no staining for glypican 1 in
MEC of an MPS VI mouse (deficiency of N-acetylgalactosamine
4-sulfatase) nor any of the secondary defects.
Defects in MEC are age dependent
No accumulation of glypican1 or of secondary markers was seen
in the MPS IIIB MEC at the age of two weeks (Table 1). Weak
staining for all the markers, indicating some accumulation, was
seen at the age of 1 month, and became strong at the age of 3
months; little difference was observed between 3 and 6 months
(Table 1).
Figure 3. Elevated level of Gsk3b in the MEC region of MPS IIIB mouse brain. The left column row shows staining for total Gsk3b and for the
phosphorylated form (P-Gsk3b Y216) in MEC of 6 months old MPS IIIB mice. The middle and right columns show absence of staining for these two
markers in LEC of the MPS IIIB mouse and in MEC of the control (heterozygous) mouse, respectively. The scale bar is 200 mm.
doi:10.1371/journal.pone.0027461.g003
Figure 4. Effect of lithium administration on Ptau AT270
inclusions in the dentate gyrus. MPS IIIB (2/2) or control (+/2)
mice were provided with LiCl in their chow, 3 g/kg, or fed regular chow,
as indicated. Each group consisted of 8 male mice. Treatment was
begun while the mice were nursing and ended with euthanasia at 3
months. The number of dentate gyrus inclusions staining with antibody
AT270 was determined by counting 12 fields that include the dentate
gyrus of the hippocampus. The bars represent the mean and standard
deviation of the number of AT270 positive inclusions.
doi:10.1371/journal.pone.0027461.g004
Medial Entorhinal Cortex in Sanfilippo B Mouse
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Discussion
This study and our earlier one [22] show three points of
similarity between the pathology of the mouse MPS IIIB brain and
that of the human brain with Alzheimer disease. First, the area
most affected in mouse MPS IIIB, the medial entorhinal cortex, is
the murine equivalent of the area in which Alzheimer disease
starts, layer 2 of the entorhinal cortex [31]. Second, Ptau was
detected in the MPS IIIB mouse brain with monoclonal antibodies
raised against Ptau from Alzheimer disease brain. And last, beta
amyloid, another hallmark of Alzheimer disease, has now been
detected in the MPS IIIB mouse brain with four antibodies raised
against different parts of beta amyloid or its precursor protein.
However, there are major differences between the two diseases.
The defects in the MPS IIIB brain do not extend much beyond the
MEC, immunoreactivity against Alzheimer Ptau is limited to a few
antibodies and all beta amyloid accumulation is intracellular.
Unlike the case in Alzheimer disease, there are no extracellular
plaques and no staining with thioflavin S in MPS IIIB. But as the
toxic form of beta amyloid is now thought to be intracellular
oligomers rather than the large aggregates in extracellular plaques
[32], the absence of plaques does not diminish the possible role of
beta amyloid in the pathogenesis of MPS IIIB. Neurons in the
MPS IIIB MEC react with A11, an antibody that recognizes
oligomers [28]; A11 may react with oligomers of beta amyloid
and/or lysozyme, which is also present at increased levels in MPS
IIIB [22].
The hyperphosphorylation of tau probably represents a late
event in the pathogenic cascade leading to neurodegeneration.
The AT270 inclusions of Ptau in the dentate gyrus require the
action of Gsk3b, as demonstrated by the marked reduction of
these bodies after treatment of the mice with lithium chloride (a
Figure 5. Elevated level of beta amyloid in the MEC region of MPS IIIB mouse brain. The left column shows staining in the MEC region of
MPS IIIB (2/2) mice, with the middle and right columns showing a control region (LEC) in the same mice and the MEC region in control (+/2) mice,
respectively. The mice were 3 months old for Abeta (N term), 6 months old for APP, Abeta 1–40, Abeta 1–42, and 10 months old for A11. The
antibodies used, from top to bottom, were: polyclonal antibody to amino acids 1–14 of amyloid beta, polyclonal antibody to amyloid precursor
protein (APP), monoclonal antibody to peptide Abeta 1–40, monoclonal antibody to Abeta 1–42, and polyclonal antibody to A11.
doi:10.1371/journal.pone.0027461.g005
Medial Entorhinal Cortex in Sanfilippo B Mouse
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specific inhibitor of Gsk3b from day 12 to day 90. It is probably
the Gsk3b activated by phosphorylation on Y216 [26] that is
responsible for the phosphorylation of tau; this form is elevated in
the MPS IIIB brain, as is total Gsk3b. We did not attempt to
determine the state of phosphorylation of the regulatory site, S9,
because phosphorylation at that site is affected by anesthesia and
post-mortem interval [33]. Since elevated P-Gsk3b was seen in
MEC but not in the dentate gyrus, it is likely that the reaction
product, Ptau, was transported from MEC to the dentate gyrus.
Other substances enriched in MEC suggest some metabolic
patterns. Gangliosides, cholesterol and GPI-linked proteins cluster
in lipid rafts [34]; therefore, the coexistent increase of GM3
ganglioside, cholesterol and glypicans in MPS IIIB MEC suggests
enrichment of these substances in rafts on the plasma membranes
of MEC neurons. The possible involvement of rafts in brain of
MPS IIIA and IIIB mice was previously suggested [35]. LC3, P62
and polyubiquitin interact during the process of autophagy [29];
the elevated level of these proteins may therefore indicate
autophagy that has not been completed. The failure of
autophagosomes to fuse with lysosomes has been suggested to be
a primary cause of pathology in lysosomal storage diseases [36].
The increase in total ubiquitin suggests inadequate proteasomal
function, resulting in a backlog of ubiquitinated proteins, while the
presence of SCMAS in lysosomes [20] suggests inadequate
lysosomal proteolysis. The presence of nitrotyrosine-modified
proteins suggests oxidative stress, which has been reported for
the brain of MPS IIIB mice [5], while the increase in O-GlcNAc-
modified proteins suggests metabolic stress [30]. The increase in
O-GlcNAc-modified proteins indicates that the lack of heparan
sulfate degradation and consequent lack of recycling of its
constituent sugars does not cause a global reduction of N-
acetylglucosamine residues on proteins, probably because suffi-
cient N-acetylglucosamine can be made de novo by the glutamine:
fructose-6-phosphate aminotransferase pathway.
What is the relationship of the primary defect (deficiency of an
enzyme of heparan sulfate degradation) to these secondary defects?
The secondary defects in MEC appear correlated with the
increase in glypican 1, as seen by examining the brain of other
MPS mouse models (Fig. 7 and Table 1). The accumulation of
glypican 1 and the secondary defects in MEC of MPS IIIA mice
are as prominent as those in the MPS IIIB mice, indicating that it
is the inability to degrade heparan sulfate and not the specific
enzyme deficiency that underlies these defects. As expected, the
secondary defects were absent in the brain of an MPS VI mouse,
which has no block in heparan sulfate degradation and no
accumulated glypican. On the other hand, the weak staining for
glypican 1 in MEC of MPS I and MPS II mouse models and the
weak or marginal staining for the secondary markers were
somewhat surprising since the enzyme deficiencies in MPS I and
MPS II result in failure to degrade both heparan sulfate and
Figure 6. Elevated levels of additional proteins and GM3 ganglioside in the MEC of MPS IIIB brain. Staining performed with antibodies
to the indicated substances was observed in the MEC region of 3 month-old MPS IIIB mice (for total ubiquitin and polyubiquitin) and 6 months for all
others. Staining was not seen in the MEC region of age-matched control mice (Naglu +/2) nor in the LEC region of MPS IIIB mice (the latter not
shown).
doi:10.1371/journal.pone.0027461.g006
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dermatan sulfate. But we note that although heparan sulfate (the
glycan) and glypican (the proteoglycan) are closely related, they
are not identical molecules, the proteoglycan being the precursor
to the glycan. Perhaps there is some difference in how the
proteoglycan in metabolized in MPS I and MPS II compared to
MPS III brain.
A second question is why MEC appears to be the most
vulnerable area of the brain with respect to these accumulations.
It may be due to the heparan sulfate proteoglycan (HSPG)
metabolism of MEC. A map of gene expression in the normal
mouse brain shows glypican 5 expression to be almost entirely in
MEC [37]. In MPS IIIB brain, MEC is enriched in the HSPG
glypican 1 and glypican 5, and perhaps some additional HSPG,
not yet identified. In the MPS IIIB MEC neurons, some glypican
(whether observed by protein or carbohydrate epitopes) may be
co-localized with Lamp1 (a marker for membranes of lysosomes
and late endosomes), but much is not. The low level of glypican
staining in lysosomes can be readily explained by the loss of the
Figure 7. Elevated levels of various proteins in MEC and in dentate gyrus of MPS IIIA brain. Staining was performed with antibodies
against the proteins shown in a 7 months-old MPS IIIA mouse brain. The first 3 rows are for the MEC region and the bottom row for dentate gyrus.
Age-matched C57BL6 mice, used as controls, showed no staining in the MEC region (not shown). The dentate gyrus showed AT270 inclusions in MPS
IIIA (2/2) mouse brain (arrows) but not in the C57BL/6 (control) brain (bottom row).
doi:10.1371/journal.pone.0027461.g007
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protein or carbohydrate epitopes during degradation of the
HSPG. On the other hand, the role of the extralysosomal glypican
and its subcellular location in the neuron are not known at this
time. It may be present on the cell surface, in transport vesicles or
in neuronal processes. Some may be present in a biosynthetic
compartment, such as the Golgi; a defect of the Golgi has been
reported in the brain of MPS IIIB mice [38]. Some HSPG may
detach from the membrane and escape into cytoplasm, perhaps
from autophagosomes that fail to fuse with lysosomes. Finally,
MEC neurons in MPS III may be unable to synthesize sufficient
lysosomal membrane to accommodate not only all the partially
degraded heparan sulfate, but also all the HSPG that is slated for
degradation, causing a backlog of HSPG outside the lysosomes.
Some or all of these proposed mechanisms may co-exist. If
accumulated HSPG is not sequestered within lysosomes, it could
become toxic to the neuron. But since accumulation of glypican is
seen only after 2 weeks of postnatal life, it is unlikely to disrupt
embryonic or early postnatal brain development.
The toxicity of extralysosomal glypican may have several causes.
Since HSPGs bind growth factors and other signaling molecules
[39], excessive glypican on the cell membrane would affect some
signaling pathways. Second, excessive glypican in a biosynthetic
compartment could result in over-modification of the carbohy-
drate moieties, endowing the carbohydrate chains with some
abnormal structure or function. Finally, polyanions such as
heparan sulfate and HSPG are known to promote beta amyloid
aggregation [40,41] and tau fiber formation [42]; their presence in
a location where they can encounter beta amyloid or Ptau would
therefore potentiate the formation of oligomers or larger
aggregates of these proteins, which in addition to being toxic,
would be difficult to degrade by both lysosomal and proteasomal
pathways. Thus the simplest unitary explanation for the
pleiotropic effects in MEC of MPS IIIB (and MPS IIIA) mice is
that the neurons in that area of the brain accumulate more HSPG
than they can sequester in lysosomes, and that the non-lysosomal
HSPG causes secondary defects and thereby exacerbates the
problems of the underlying storage disease.
Materials and Methods
Mouse colony and brain collection
Animal studies were approved by the Chancellor’s Animal
Research Committee of the University of California Los Angeles,
protocol ARC 1994-075. MPS IIIB [2] and MPS I [3] mice were
from colonies developed and maintained by us on a C57BL6
background. For brain collection, the mice were euthanized with
pentobarbital (100 mg/kg). The brains were removed and post-
fixed in 3.65% phosphate-buffered formaldehyde (Fischer Scien-
tific) at 4uC and stored at 4uC until used. In some of the early
experiments, the mice were first perfused through the heart as
described [22]. Brains from other mouse models were provided by
Steven Walkley (MPS IIIA), Joseph Muenzer (MPS II) and Alberto
Auricchio (MPS VI). Sections, 40 mm thick, were cut sagittally on
a Leica Microsystems Vibratome VT1000S.
Immunohistochemistry
Primary antibodies. These are listed together with the
provenance, distributors and catalogue numbers. Glypican 1,
rabbit polyclonal, Novus Biologicals NBP1-18666; glypican 2, goat
polyclonal, R&D systems AF2355; glypican 5 rabbit polyclonal,
Santa Cruz Biotechnology sc84278; heparan sulfate HepSS1
mouse monoclonal IgM, Seikagaku/Amsbio 270426; D heparan
sulfate F69-3G10, mouse monoclonal IgG, Seikagaku 370260,
used with heparitinase (heparan lyase) from Flavobacterium
heparinum, Seikagaku 100703; PHF tau mouse monoclonal IgG,
clone AT100, Endogen MN1060; PHF tau mouse monoclonal
IgG, clone AT270, Pierce Endogen MN1050; Gsk3b rabbit
polyclonal, GenScript A00196; P-Gsk3b (Y216) rabbit polyclonal,
Abcam ab75745; beta amyloid 1-14, rabbit polyclonal, Abcam
ab2539; beta amyloid peptide 1–40, mouse monoclonal IgG,
Covance SIG-39140; beta amyloid peptide 1–42 mouse
monoclonal IgG clone 11A50-B10, Covance SIG-39142;
amyloid precursor protein 44–63, goat polyclonal, Abcam
ab77994; A11, rabbit polyclonal, Invitrogen AHB0052; LC3,
rabbit polyclonal, Novus Biologicals NB100-2331; ubiquitin,
rabbit polyclonal, DAKO z0458; ubiquitin (Ubi1, polyubiquitin
chains), mouse monoclonal IgG, Abcam ab7254; p62, mouse
monoclonal IgG, Novus Biologicals H00008878-M01; GM3
ganglioside, mouse monoclonal IgM, clone GMR6, Seikagaku
370695; nitrotyrosine, rabbit polyclonal, Millipore 06–284;
Lamp1, rat monoclonal IgG, clone 1D4B, Santa Cruz SC19992;
O-GlNAc, mouse monoclonal IgM (CTD110.6) was provided by
Gary Hart [43]; SCMAS, rabbit polyclonal, was commercially
prepared for us [20].
Secondary antibodies. Biotin-labeled antibodies were
obtained from Jackson ImmunoResearch Laboratories: donkey
anti-mouse IgG (715-066-150), donkey anti-mouse IgM (715-066-
020), donkey anti-rabbit IgG (711-066-152); and from Vector
Table 1. Comparison of staining for markers in MEC of mice of different ages and with different mucopolysaccharide storage
diseases.
MPS IIIB IIIB IIIB IIIB IIIA IIIA I I II VI
Age (mo) 0.5 1 3 6 4 7 6 12 7 12
Glypican 1 - + ++ ++ ++ ++ + + + -
SCMAS - + ++ ++ ++ ++ + ++ + -
LC3 - + ++ ++ ++ ++ - +/2 +/2 -
Nitroty - + ++ ++ ++ ++ - +/2 +/2 -
O-GlcNAc - + ++ ++ + nd + + -
Staining: ++ intense to moderate.
+ weak.
+/- a few positive cells.
2 not detected.
nd not determined.
doi:10.1371/journal.pone.0027461.t001
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Research Lab, horse anti-goat IgG (BA9500). Fluorescent
antibodies were obtained from Invitrogen: AlexaFluor 488
donkey anti- mouse IgG (A21202); AlexaFluor 488 donkey anti-
rat IgG, A21208; AlexaFluor 647 donkey anti-rabbit IgG
(A31573).
Sample preparation for light microscopy and confocal
microscopy
Sections, 40 mm thick, were cut sagittally on vibratome VT
1000S (Leica microsystems). Slices were permeabilized in 1% (v/v)
triton X-100/phosphate-buffered saline (PBS) for 1h at ambient
temperature. After washing in the buffer, slices were placed on
vectabond-coated glass slides and dried overnight. They were then
rehydrated in PBS and washed in ice-cold methanol for 10 min.
For immunohistochemistry, slices were additionally washed in
0.3% (v/v) H2O2 in methanol at ambient temperature and
incubated sequentially with 0.5% (v/v) normal donkey serum,
primary antibody and biotin-labeled F(ab’)2 donkey secondary
antibody in Tris-buffered saline (pH 7.5) containing 2% (w/v)
bovine serum albumin and 0.02% (v/v) Tween 20 (Tween 20 was
excluded when staining for ganglioside GM3). Antigen retrieval by
a brief wash in 60% (v/v) formic acid was included prior to
staining for Abeta 1–40, Abeta 1–42 and A11. The signal was
detected by the Vecstain ABC Elite kit, visualized with
diaminobenzidine and counterstained with hematoxylin.
For staining with 3G10 antibody, vibratome sections were first
incubated at 37oC for 2 h with heparitinase (5 or 10 munit/ml) in
100 mM NaCl, 1 mM CaCl2, 50 mM Hepes pH 7.0, 0.01%
bovine serum albumin and protease inhibitors (Thomas Scientific
#78425), in a total volume of 0.5 ml.
For double immunostaining, the signal was detected by
secondary antibodies conjugated to Alexa 488 and Alexa 647
(Invitrogen). Images were acquired by laser scanning confocal
microscopy (Pascal 5, Zeiss) and processed by Axiovision software
(Carl Zeiss Microimaging) and Adobe Photoshop.
Lithium treatment
Eight Naglu2/2 and 8 Naglu +/2 male mice were fed standard
chow (Teklad 7013) containing 3 g/kg LiCl, purchased from
Harlan Laboratories; 8 Naglu 2/2 and 8 Naglu+/2 male mice
were fed the standard chow. The LiCl chow contained 0.05 g/kg
blue food coloring for easy identification. Since lithium might
cause loss of sodium, the mice receiving lithium were provided
with a small bottle of water containing 0.9% NaCl in addition to
their regular water supply; however, they used little if any of the
saline supplement. To get the pups used to the taste of LiCl, the
experiment was started at P12, with the mother receiving chow
containing 2 g/kg LiCl, and the pups were switched to the 3 g/kg
regimen upon weaning (P20). The mice were sacrificed at P89–92
for examination of brain pathology.
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